Hormonal
Tirzepatide (5-15 mg weekly) significantly improves glycemic control (HbA1c reduction of 1.87-2.58%) and induces substantial weight loss (up to 13.9 kg) in patients with type 2 diabetes, outperforming GLP-1 receptor agonists (semaglutide, dulaglutide) and basal insulin (degludec, glargine).
If you have type 2 diabetes, Tirzepatide is a once-weekly injection that significantly lowers blood sugar (HbA1c) and helps you lose a substantial amount of weight, often more effectively than other common diabetes medications like semaglutide or basal insulin. It works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles glucose and fat. You start at a low dose (2.5 mg) and increase it every few weeks to minimize stomach upset, which is common but usually temporary. It is approved for adults with T2DM, including those who are insulin-dependent.
The magnitude of tirzepatide’s effects and the efficacy relative to other anti-diabetes medications on weight, glycemic control, and beta-cell function may prove beneficial for the treatment of early type 2 diabetes mellitus.
Why this rating
Based on multiple Phase III randomized controlled trials (SURPASS 1-5) with large sample sizes and rigorous design.
Source
Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
Tanzila S Razzaki et al. · Therapeutics and Clinical Risk Management · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →